C. JARMOUMI ET AL.
REFERENCES
[1] M. A. Naylor, M. A. Stephen, J. Nolan, B. Sutton, J. H. Tocher, E. M.
Fielden, J. E. Adams, I. Strafford, Anticancer Drug Des. 1993, 8,
439–461.
[2] J. Harmenberg, A. Akesson, A. Graslund, T. Malmblad, S. Cox, Antiviral
Res. 1991, 15, 193–204.
[3] A. Fournet, R. Mahieux, M. Fakhfakh, X. Franck, R. Hocquemiller, B.
Figadere, Bioorg. Med. Chem. Lett. 2003, 13, 891–894.
[4] M. H. Munos, J. Mayrargue, A. Fournet, J. C. Gantier, R. Hocquemiller,
H. Moskowitz, Chem. Pharm. Bull. 1994, 42, 1914–1916.
[5] G. W. H. Cheeseman, R. F. Cookson, In: The Chemistry of Heterocyclic
Compounds, Vol. 35 (Eds: A. Weissberger, E. C. Taylor,), John Wiley and
Sons, New York, 1979, 1.
Figure 8. Structure of compound 8 at 293 K, projection along ac. This
poc
[6] T. H. Corbett, P. M. Lorusso, L. Demchick, C. Simpson, S. Pugh, K. White,
J. Kushner, L. Polin, J. Meyer, J. Czarnecki, L. Heilbrun, J. P. Horwitz, J. L.
Cross, C. H. Behrens, B. A. Harrison, R. J. McRipley, G. Trainor, Invest.
New Drugs 1998, 16, 129–139.
[7] P. M. Lorusso, R. Parchement, L. Demchik, L. Polin, J. Dzubow, C.
Behrens, B. Harrison, G. Trainor, T. H. Corbett, Invest. New Drugs
1998–1999, 16, 287–296.
[8] R. H. Shoemaker, Cancer Treat. Rep. 1986, 70, 9–12.
[9] J. R. Rigas, V. A. Miller, W. P. Tong, N. Roistacher, M. G. Kris, J. P. Orazem,
C. W. Young, R. P. Warrell, Cancer Chemother. Pharmacol. 1995, 35,
483–488.
unit cell (Fig. 8). The structure was measured at room
temperature; the crystallographic data are presented in Table 1.
Molecules are stacked with a pseudo-hydrogen bond (Table 4).
As for compound 7, the single crystal was a pure enantiomer
although the optical rotatory power of the powder was equal to
zero. The absolute configuration of the measured single crystal is
the same that of compound 7 single crystals.
[10] K. Yamni, C. Jarmoumi, N. Dohou, B. Lakhrissi, M. Massoui, A.
´
Ouazzani, A. Douira, Effet in vitro de quelques molecules de synthese
derivees de la quinoxalinone sur Pestalotia Cruenta et Alternaria Citri.
`
CONCLUSIONS
´
´
`
6eme Congres de l’Association Marocaine de Protection des Plantes,
`
Rabat, 29–30 Novembre 2006, 41–47.
[11] C. Jarmoumi, K. Yamni, B. Lakhrissi, M. Massoui, EM. Essassi, O.
An intramolecular rearrangement of 5,6-anhydro-1,2-O-isopro-
pylidene-a-D-glucofuranose in the corresponding 3,6-anhydro
has been put forward in the synthesis of 2-O-(5-deoxy-
1,2-O-isopropylidene-a-D-glucofuranos-5-yloxy)-quinoxaline 7, and
8. The crystal structure of these compounds have been
determined at room temperature, they both crystallize in a
monoclinic system, C2 and P21, respectively. The compound
7 shows a first-order solid–solid phase transition at 198.9 ꢂ 0.4 K
with a low enthalpy variation of 0.35 ꢂ 0.06 kJ ꢃ molꢀ1. The crystal
structure of the low-temperature form has also been determined,
it crystallizes in the C2 group but the asymmetric unit is
composed of three independent molecules.
`
Touhami, A. Douira, N. Joly, V. Lequart, P. Martin, Synthese et
effet in vitro de certaines quinoxalinones et glycoquinoxalinones
`
sur deux pathogenes foliaires du poirier: Pestalotia cruenta et
´ ´
`
Alternaria citri. 6eme Rencontre nationale sur la chimie heterocy-
´
clique, Faculte des Sciences, CA 140, Casablanc, Maroc, 25–26 mai
2007.
[12] V. S. H. Krishnan, K. S. Chowdary, P. K. Dubey, S. Vijay, Indian J. Chem.
2001, 40B, 565–573.
[13] Y. S. Hong, H. M. Kim, Y. T. Park, H. S. Kim, Bull. Korian Chem. Soc. 2000,
21, 133–136.
[14] P. Y. Goueth, G. Ronco, P. Villa, Carbohydr. Chem. 13, 1994, 679–696.
[15] B. Lakhrissi, E. M. Essassi, M. Massoui, G. Goethals, V. Lequart, E.
Monflier, R. Cecchelli, P. Martin, Carbohydr. Chem. 23, 2004, 389–
401.
Acknowledgements
[16] M. P. Molas, M. I. Matheu, S. Castillon, Tetrahedron 1999, 55,
14649–14664.
`
This work was supported by ‘Ministere Marocain de l’Enseigne-
ment Superieur’ and by Franco–Moroccan cooperation.
[17] H. B. Mereyala, P. Pola, Tetrahedron: Asymmetry 2003, 14, 2683–
2685.
´
Copyright ß 2009 John Wiley & Sons, Ltd.
J. Phys. Org. Chem. 2009, 22 585–592